[{"_1":2,"_67":-5,"_68":-5},"loaderData",{"_3":4,"_12":13},"root",{"_5":-5,"_6":7,"_8":9,"_10":11},"user","recaptchaSiteKey","6Ler9Q4rAAAAAIntb4jBhAbPRXMJSQVneAzxg5M8","sentryTrace","b42d6387ffc6fb209d1635ad682d7c15-ac313be1dba0127b-0","sentryBaggage","sentry-environment=production,sentry-public_key=fbef35ac88c344bffa6f98009cf3736c,sentry-trace_id=b42d6387ffc6fb209d1635ad682d7c15,sentry-org_id=4505908219871232,sentry-sampled=false,sentry-sample_rand=0.8212332907267768,sentry-sample_rate=0.5","routes/domain.$domainId",{"_14":15,"_63":64,"_5":-5,"_65":66},"domain",{"_16":17,"_14":18,"_19":20,"_21":22,"_23":24,"_25":26,"_27":28,"_29":-5,"_30":-5,"_31":-5,"_32":33,"_43":44,"_49":50,"_61":62},"id","cmhe9uov10014ju02n9lx1ylm","www.dovatohcp.com","screenshotPath","sites/www.dovatohcp.com/screenshot.jpg","htmlPath","sites/www.dovatohcp.com/index.html","metaDescription","Discover DOVATO (dolutegravir/lamivudine) a treatment for HIV-1 infection in treatment-naïve & virologically suppressed patients. See full Indication, Boxed Warning & PI.","importantText","HIV-1 Treatment Option | DOVATO (dolutegravir/lamivudine) \n\n#### You are now leaving this site.\n\nYou are about to leave a ViiV Healthcare website. By clicking “Continue,” you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.\n\nCancelContinue\n\nThis site is intended for US healthcare professionals only.\n\nContinue[Switch to Patient Site](https://www.dovato.com/)\n\nFor US Healthcare Professionals Only\n\n* [\n \n Full Prescribing Info with Boxed Warning\n \n ](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Dovato/pdf/DOVATO-PI-PIL.PDF)\n* [\n \n Register for Updates\n \n ](https://www.dovatohcp.com/resources/connect-with-us/)\n* [\n \n Request a Rep\n \n ](https://www.dovatohcp.com/request-a-rep/)\n* [\n \n Patient Site\n \n ](https://www.dovato.com/)\n* [\n \n ViiV MedInfo\n \n ](https://viivhcmedinfo.com/our-hiv-medicines/dovato/)\n\n[![DOVATO logo: dolutegravir 50 mg/ lamivudine 300 mg tablets.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/01-global/logo-dovato.svg)](https://www.dovatohcp.com/)\n\n* [\n \n Patient Profiles\n \n ](https://www.dovatohcp.com/patient-profiles/)\n* [\n \n Efficacy and Resistance\n \n ](https://www.dovatohcp.com/efficacy-and-resistance/)\n * [\n \n Efficacy and Resistance\n \n ](https://www.dovatohcp.com/efficacy-and-resistance/)\n * [\n \n Pivotal Trials\n \n ](https://www.dovatohcp.com/efficacy-and-resistance/long-term/)\n * [\n \n TANGO \n \n DOVATO vs TAF Regimens to 4 Years\n \n \n \n ](https://www.dovatohcp.com/efficacy-and-resistance/long-term/tango/)\n * [\n \n GEMINI 1 & 2 \n \n DOVATO vs 3DR to 3 Years\n \n \n \n ](https://www.dovatohcp.com/efficacy-and-resistance/long-term/gemini/)\n * [\n \n Head to Head\n \n ](https://www.dovatohcp.com/efficacy-and-resistance/head-to-head/)\n * [\n \n DYAD \n \n DOVATO vs Continuing BIKTARVY\n \n \n \n ](https://www.dovatohcp.com/efficacy-and-resistance/head-to-head/dyad/)\n * [\n \n PASO DOBLE \n \n DOVATO vs BIKTARVY Noninferiority\n \n \n \n ](https://www.dovatohcp.com/efficacy-and-resistance/head-to-head/paso-doble/)\n * [\n \n Real-World Evidence\n \n ](https://www.dovatohcp.com/efficacy-and-resistance/real-world-evidence/)\n * [\n \n OPERA & TANDEM \n \n Data Complement to Phase 3 Clinical Trials\n \n \n \n ](https://www.dovatohcp.com/efficacy-and-resistance/real-world-evidence/opera-and-tandem/)\n* [\n \n Safety\n \n ](https://www.dovatohcp.com/safety/)\n* [\n \n Dosing\n \n ](https://www.dovatohcp.com/dosing/)\n* [\n \n Samples and Savings\n \n ](https://www.dovatohcp.com/samples-and-savings/)\n* [\n \n Resources\n \n ](https://www.dovatohcp.com/resources/)\n * [\n \n Resources\n \n ](https://www.dovatohcp.com/resources/)\n * [\n \n Educational Resources\n \n ](https://www.dovatohcp.com/resources/educational-resources/)\n * [\n \n Webinars and Videos\n \n ](https://www.dovatohcp.com/resources/webinars-and-videos/)\n * [\n \n Connect With Us\n \n ](https://www.dovatohcp.com/resources/connect-with-us/)\n\n![Homepage banner.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/background.jpg)\n\n![Homepage banner.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/people.png)![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/timeline_left.svg)![Homepage banner.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/title.svg)![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/timeline_right.svg)![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/year_2025.svg)![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/year_2026.svg)![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/year_2027.svg)![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/animation/year_2028.svg)\n\nNot actual patients.\n\nBreadth of Data Across Randomized Controlled Trials: DOVATO Achieves and Maintains Viral Suppression With Fewer Medicines1-7\n----------------------------------------------------------------------------------------------------------------------------\n\n[\n\n![Purple bar graph icon.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/icon-graph.svg)\n\n](https://www.dovatohcp.com/efficacy-and-resistance/long-term/tango/)\n\n[](https://www.dovatohcp.com/efficacy-and-resistance/long-term/tango/)\n\n[\n\n### Proven Efficacy and High Barrier to Resistance in GEMINI & TANGO\n\n](https://www.dovatohcp.com/efficacy-and-resistance/long-term/tango/)\n\n[Durable virologic suppression for patients in](https://www.dovatohcp.com/efficacy-and-resistance/long-term/tango/) [GEMINI](/content/cf-viiv/dovato-hcp-v4/en_US/home/efficacy-and-resistance/long-term/gemini.html) (3 years)1,2 and [TANGO](/content/cf-viiv/dovato-hcp-v4/en_US/home/efficacy-and-resistance/long-term/tango.html) (4 years)3-5\\*†\n\nUncover Insights\n\n[\n\n![Pink bar graph icon. ](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/icon-comparison graph.svg)\n\n### DOVATO vs BIKTARVY\n\nSee data from 2 head-to-head trials comparing efficacy and safety6,7\n\nLearn More\n\n\n\n](https://www.dovatohcp.com/efficacy-and-resistance/head-to-head/dyad/)\n\n[\n\n![Fewer medications icon. ](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/icon-fewer medicines.svg)\n\n### Fewer Medicines\n\nDOVATO is a complete, booster-free, single-tablet regimen for your patients\n\nDiscover Dosing\n\n\n\n](https://www.dovatohcp.com/dosing/)\n\n\\*In a pooled analysis from GEMINI 1 & 2, identical, Phase 3, randomized, double-blind to Week 96 (open-label Week 96 to Week 144), noninferiority trials in treatment-naïve adults with HIV-1 (≥18 years old), the proportion of participants with HIV-1 RNA <50 copies/mL at Week 48 (primary endpoint) was 91% vs 93% for the DOVATO (N=716) and DTG + TDF/FTC (N=717) arms, respectively (treatment difference: -1.7% \\[95% CI; -4.4%, 1.1%\\]). In GEMINI 1 & 2, CVW occurred in 21 participants (12 for DOVATO, 9 for DTG + TDF/FTC) at 144 weeks. Among all trial participants, 1 in the DOVATO arm developed treatment-emergent resistance. CVW was defined as either virologic nonresponse (a decrease in plasma HIV-1 RNA of <1 log10 copies/mL by Week 12, with subsequent confirmation, unless plasma HIV-1 RNA is <200 copies/mL or confirmed plasma HIV-1 RNA ≥200 copies/mL on or after Week 24) or virologic rebound (confirmed rebound in plasma HIV-1 RNA levels to ≥200 copies/mL after prior confirmed suppression to <200 copies/mL). The most common (≥2%) drug-related adverse events (all Grades) in the DOVATO arm (N=716) and DTG + TDF/FTC arm (N=717), respectively, were headache (3%, 4%), nausea (2%, 6%), diarrhea (2%, 3%), insomnia (2%, 3%), fatigue (including fatigue, asthenia, and malaise \\[2%, 2%\\]), anxiety (2%, <1%), and dizziness (1%, 2%). 4% and 5% of participants, respectively, experienced adverse events that led to withdrawal.1,2\n\n†TANGO is a Phase 3, noninferiority trial in virologically suppressed (HIV-1 RNA <50 copies/mL) adults with HIV-1 in which all participants were on a TCR and stable for >6 months. The proportion of participants with HIV-1 RNA ≥50 copies/mL at Week 48 (primary endpoint) was <1% vs <1% for the DOVATO (N=369) and TCR (N=372) arms, respectively (treatment difference: -0.3% \\[95% CI; -1.2%, 0.7%\\]). Patients in the TAF-containing regimen were switched to DOVATO at Week 148 if HIV-1 RNA <50 copies/mL (Late Switch). In TANGO, no treatment-emergent resistance was detected through Week 196. Only participants meeting CVW criteria (1 for DOVATO, 3 for TCR) were evaluated for treatment-emergent resistance. CVW was defined as HIV-1 RNA ≥50 copies/mL followed by a second consecutive HIV-1 RNA ≥200 copies/mL. At Week 144, the most common (≥0.5%) drug-related adverse events (Grades 2-5) in the DOVATO arm (n=369) and TCR arm (n=371), respectively, were insomnia (1%, 0), depression (<1%, <1%), constipation (<1%, <1%), weight increase (<1%, <1%), flatulence (<1%, 0), and nausea (0, <1%). 6% and 2% of participants, respectively, experienced adverse events that led to withdrawal. At Week 196 among patients who switched to DOVATO at Week 1 (Early Switch), 6% experienced at least one Grade 2-5 drug-related AE. For these Early-Switch patients, the most common drug-related AEs (≥2%) measured at Week 196 were weight increase (2%) and insomnia (2%). 7% experienced an AE leading to withdrawal at Week 196.3-5\n\nHear Patient Concerns\n---------------------\n\n#### Consider What's to Come; Treat Ahead\n\nYour patients can be on antiretroviral therapies for decades. Consider the right treatment not only for now but also for their next steps. As their needs change, choose a treatment that fits them.\n\n[Explore Profiles](https://www.dovatohcp.com/patient-profiles/)\n\n![Four people smiling. Not actual patients. ](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/img-hear-patient-concerns-lg.png)\n\nShared Conversations\n--------------------\n\n![](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/img-video-shared-choices-shared-voices-lg.png)\n\nVideo Player is loading.\n\nPlay Video\n\nPlaySkip BackwardSkip Forward\n\nMute\n\nCurrent Time 0:00\n\n/\n\nDuration 17:07\n\nLoaded: 0.58%\n\n00:00\n\nStream Type LIVE\n\nSeek to live, currently behind liveLIVE\n\nRemaining Time \\-17:07\n\n1x\n\nPlayback Rate\n\nChapters\n\n* Chapters\n\nDescriptions\n\n* descriptions off, selected\n\nCaptions\n\n* captions settings, opens captions settings dialog\n* captions off, selected\n* Unknown Captions\n\nAudio Track\n\n* en (Main), selected\n\nPicture-in-PictureFullscreen\n\nThis is a modal window.\n\nBeginning of dialog window. Escape will cancel and close the window.\n\nTextColorWhiteBlackRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-Transparent\n\nText BackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-TransparentTransparent\n\nCaption Area BackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityTransparentSemi-TransparentOpaque\n\nFont Size50%75%100%125%150%175%200%300%400%\n\nText Edge StyleNoneRaisedDepressedUniformDrop shadow\n\nFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps\n\nResetDone\n\nClose Modal Dialog\n\nEnd of dialog window.\n\nClose Modal Dialog\n\nThis is a modal window. This modal can be closed by pressing the Escape key or activating the close button.\n\nTranscript\n\nShared Conversations\n--------------------\n\n#### Follow the Journey of a Patient and His HCP\n\nHow can you discuss DOVATO with your patients? Learn from Dr. Ogechika Alozie and his patient Hector as they discuss why they chose DOVATO.\n\n1:50 – Introduction \n3:00 – Clinical Insights That Drive Impact \n4:29 – Patient-Centered Conversations \n5:25 – Why DOVATO Was the Right Choice for Hector \n11:38 – Data-Driven Decisions \n12:39 – Closing\n\nPlay Video\n\n![A Patient Support Card: Patients may pay as little as $0 copay per fill.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/img_coupon_card@2x.png)\n\nViiVConnect Savings Card\n------------------------\n\nEligible, commercially insured patients pay as little as $0 with a ViiVConnect Savings Card.‡\n\n[Discover Savings](/samples-and-savings/)\n\n‡Subject to eligibility and program terms and conditions; ViiVConnect programs do not constitute health insurance. [Restrictions apply](https://myviivcard.com/get-a-card/).\n\n![A Patient Support Card: Patients may pay as little as $0 copay per fill.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/0-0-home/img_coupon_card@2x.png)\n\nConnect With Us\n---------------\n\n[\n\n### Request a Rep\n\nSchedule a visit from a ViiV Healthcare representative in your area\n\n\n\n](https://www.dovatohcp.com/request-a-rep/)\n\n[\n\n### Call Us\n\n1-877-844-8872, Monday–Friday 8:30 am-5:30 pm ET\n\n\n\n](tel:1-877-844-8872/)\n\n[\n\n### Medical Chat\n\nIf you have a question, medical experts are available Monday–Friday 9 am-6 pm ET\n\n\n\n](https://viivhcmedinfo.com/contact/contact-viiv/)\n\nAE=adverse event; CI=confidence interval; CVW=confirmed virologic withdrawal; DTG=dolutegravir; FTC=emtricitabine; HCP=healthcare provider; TAF=tenofovir alafenamide; TCR=TAF-containing regimen; TDF=tenofovir disoproxil fumarate.\n\nReferences:\n\n1. Cahn P, Madero JS, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naïve adults with HIV-1 infection. AIDS. 2022;36(1):39-48. doi:10.1097/QAD.0000000000003070\n2. Cahn P, Madero JS, Arribas JR, et al; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155. doi:10.1016/S0140-6736(18)32462-0\n3. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920-1929. doi:10.1093/cid/ciz1243\n4. Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75(6):975-986. doi:10.1093/cid/ciac036\n5. De Wit S, Bonnet F, Osiyemi O, et al. Durable efficacy of switching from a 3- or 4-drug tenofovir alafenamide–based regimen to the 2-drug regimen dolutegravir/lamivudine in the TANGO study through week 196. J Acquir Immune Defic Syndr. 2024;96(2):156-160. doi:10.1097/QAI.0000000000003395\n6. Rolle C-P, Castano J, Nguyen V, Hinestrosa F, DeJesus E. Efficacy, safety, and tolerability of switching from bictegravir/emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine among adults with virologically suppressed HIV: the DYAD study. Open Forum Infect Dis. 2024;11(10):1-10. doi:10.1093/ofid/ofae560\n7. Ryan P, et al. Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial. Abstract presented at: AIDS 2024; July 22-26, 2024; Virtual and Munich, Germany. Oral abstract OAB3606LB.\n\nPMUS-DLLWCNT240045 January 2025\n\n### INDICATION\n\n### IMPORTANT SAFETY INFORMATION\n\n### INDICATION\n\nDOVATO is indicated as a complete regimen to treat HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of DOVATO.\n\n### IMPORTANT SAFETY INFORMATION\n\nBOXED WARNING: PATIENTS CO-INFECTED WITH HEPATITIS B VIRUS (HBV) AND HIV-1: EMERGENCE OF LAMIVUDINE-RESISTANT HBV AND EXACERBATIONS OF HBV\n\nAll patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.\n\nSevere acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment.\n\n### Contraindications\n\n* Do not use DOVATO in patients with previous hypersensitivity reaction to dolutegravir or lamivudine\n* Do not use DOVATO in patients receiving dofetilide\n\n### Warnings and precautions\n\nHypersensitivity Reactions:\n\n* Hypersensitivity reactions have been reported with dolutegravir and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury \n \n* Discontinue DOVATO immediately if signs or symptoms of severe skin or hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated\n\nHepatotoxicity:\n\n* Hepatic adverse events have been reported, including cases of hepatic toxicity (elevated serum liver biochemistries, hepatitis, and acute liver failure), in patients receiving a dolutegravir-containing regimen without pre-existing hepatic disease or other identifiable risk factors\n* Patients with underlying hepatitis B or C or marked elevations in transaminases prior to treatment may be at increased risk for worsening or development of transaminase elevations with use of DOVATO. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, particularly in the setting where anti-hepatitis therapy was withdrawn \n \n* Monitoring for hepatotoxicity is recommended\n\nLactic Acidosis and Severe Hepatomegaly With Steatosis: \nFatal cases have been reported with the use of nucleoside analogs, including lamivudine. Discontinue DOVATO if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.\n\nAdverse Reactions or Loss of Virologic Response Due to Drug Interactions with concomitant use of DOVATO and other drugs may occur (see Contraindications and Drug interactions).\n\nImmune Reconstitution Syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported with the use of DOVATO.\n\n### Adverse reactions\n\nThe most common adverse reactions (incidence ≥2%, all grades) with DOVATO were headache (3%), nausea (2%), diarrhea (2%), insomnia (2%), fatigue (2%), and anxiety (2%).\n\n### Drug interactions\n\n* Consult full Prescribing Information for DOVATO for more information on potentially significant drug interactions\n* DOVATO is a complete regimen. Coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended \n \n* Drugs that induce or inhibit CYP3A or UGT1A1 may affect the plasma concentrations of dolutegravir \n \n* Administer DOVATO 2 hours before or 6 hours after taking polyvalent cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, DOVATO and supplements containing calcium or iron can be taken with food\n\n### Use in specific populations\n\n* Pregnancy: There are insufficient human data on the use of DOVATO during pregnancy to definitively assess a drug-associated risk for birth defects and miscarriage. An Antiretroviral Pregnancy Registry has been established \n \n* Lactation: Potential risks of breastfeeding include HIV-1 transmission, developing viral resistance in HIV-positive infants, and adverse reactions in a breastfed infant \n \n* Renal Impairment: DOVATO is not recommended for patients with creatinine clearance <30 mL/min. Patients with a sustained creatinine clearance between 30 and 49 mL/min should be monitored for hematologic toxicities, which may require a dosage adjustment of lamivudine as an individual component\n* Hepatic Impairment: DOVATO is not recommended in patients with severe hepatic impairment (Child-Pugh Score C)\n\nPlease see full [Prescribing Information](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Dovato/pdf/DOVATO-PI-PIL.PDF), including Boxed Warning, for DOVATO.\n\nPMUS-DLLWCNT240058 January 2025\n\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at [www.gsk.public.reportum.com](https://gsk.public.reportum.com) or 1-877-844-8872, or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).\n\n[![ViiV Healthcare logo.](/content/dam/cf-viiv/dovato-hcp-v4/en_US/01-global/logo-viiv-healthcare.svg)](https://viivhealthcare.com/en-us/ \"ViiV Healthcare logo\")\n\nBIKTARVY and GENVOYA are trademarks of Gilead Sciences, Inc. All other trademarks are owned by or licensed to the ViiV Healthcare group of companies. \n \nThis site is funded and developed by ViiV Healthcare. \nThis site is intended for US healthcare professionals only. \n©2025 ViiV Healthcare or licensor. \nPMUS-DLLWCNT240055 February 2025 \nProduced in USA.\n\nYour Privacy Choices\n\n* [Terms of Use](https://viivhealthcare.com/en-us/terms-of-use/)\n* [Privacy Notice](https://viivhealthcare.com/en-us/privacy-notice/)\n* [Patient Support](https://www.viivconnect.com/)\n* [Interest-based Ads](https://viivhealthcare.com/en-us/about-our-ads/)\n* [Contact Us](https://contactus.viivhealthcare.com/hcp/speak-to-viiv-request/)\n* [ViiV Medical Information](https://viivhcmedinfo.com/)\n* [Site Map](https://www.dovatohcp.com/site-map/)\n* [Unsubscribe](https://privacyportal-de.onetrust.com/webform/0a84bb21-f26f-4cf7-8095-11a164a1de5b/0999a50d-0d93-4b13-a117-f3bdff9ebbc8/)\n\nThis site uses cookies and similar technologies (collectively, \"cookies\") to enhance your website experience and track the site's performance. Strictly necessary cookies are automatically enabled. By selecting \"Accept All Cookies\" you agree to our use of all cookies in accordance with our [Privacy Notice](https://viivhealthcare.com/en-us/privacy-notice/).\n\nCUSTOMIZE COOKIES ACCEPT ALL COOKIES\n\nManaging Privacy Options\n\nOPT OUT OF SALE AND SHARING OF INFORMATION\n\nYour state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for \"Targeting Cookies,\" and selecting the \"Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the \"Cookies and Targeted Advertising Choices,\" section in the Privacy Notice and submit the required form.\n\nStrictly Necessary Cookies Always Active\n\nNecessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms.\n\nPerformance Cookies OFF\n\nEnable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages.\n\nTargeting CookiesOFF\n\nAllow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.\n\nConfirm my choices","summary","The website provides information about DOVATO, a treatment option for HIV-1, specifically targeting US healthcare professionals.","notes","requests","dataTransferred","brands",[34],{"_16":35,"_36":37,"_38":39,"_40":41,"_42":-5},"cmhe9uksd000ql402jjiqj7xh","name","DOVATO","description","DOVATO is a complete, booster-free, single-tablet regimen for the treatment of HIV-1, designed for adults and adolescents with no prior antiretroviral treatment history or those who are virologically suppressed.","toCheck",true,"parentId","iabCategories",[45],{"_46":47,"_36":48,"_38":48},"code","IAB7","Health & Fitness","iabProducts",[51,58],{"_36":52,"_53":52,"_54":-5,"_55":-5,"_16":56,"_57":-5},"Health and Medical Services","tier1","tier2","tier3",1378,"parent_id",{"_36":59,"_53":59,"_54":-5,"_55":-5,"_16":60,"_57":-5},"Pharmaceuticals",1473,"tags",[],"creatives",[],"cdnUrl","https://d3a7qprliuujyh.cloudfront.net","actionData","errors"]

www.dovatohcp.com

Summary

Associated Brands

IAB Categories

IAB Ad Products

Tags

Creatives